7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)
Chi, K.N., Hotte, S.J., Yu, E., Tu, D., Eigl, B., Tannock, I., Saad, F., North, S., Powers, J., Eisenhauer, E.Volume:
7
Language:
english
Journal:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(09)71382-5
Date:
September, 2009
File:
PDF, 53 KB
english, 2009